Arianna Di Napoli

Prof. Arianna Di Napoli

Dept. Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Lazio, Italy
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2016 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
ANArianna Di Napoli
Arianna Di Napoli
PJPreti Jain
Preti Jain
EDEnrico Duranti
Enrico Duranti
EMElizabeth Margolskee
Elizabeth Margolskee
WAwalter arancio
walter arancio
GBGovind Bhagat
Govind Bhagat

17 June 2021 in Blood
Verified
Journal Article
Open access
PDF file
Tiziana VaisittiTiziana Vaisitti
Tiziana Vaisitti
FAFrancesca Arruga
Francesca Arruga
NVNicoletta Vitale
Nicoletta Vitale
TLThanh-Trang Lee
Thanh-Trang Lee
MKMira Ko
Mira Ko
Silvia DeaglioSilvia Deaglio
Silvia Deaglio
Richter syndrome (RS) represents the transformation of chronic lymphocytic leukemia (CLL), typically to an aggressive lymphoma. Treatment options for RS are limited and the disease is often fatal. Receptor tyrosine kinase–like orphan receptor 1 (ROR1) is expressed on CLL cells and other cancers but not on healthy adult tissues, making it an attractive, tumor-specific therapeutic target. VLS-101 is being developed as an antibody-drug conjugate (ADC) for therapy of ROR1-expressing (ROR1+) cancers. VLS-101 comprises UC-961 (a humanized immunoglobulin G1 monoclonal antibody that binds an extracellular epitope of human ROR1), a maleimidocaproyl-valine-citrulline-para-aminobenzoate linker, and the antimicrotubule cytotoxin monomethyl auristatin E (MMAE). VLS-101 binding to ROR1 results in rapid cellular internalization and delivery of MMAE to induce tumor cell death. We studied 4 RS patient-derived xenografts (RS-PDXs) with varying levels of ROR1 expression (11%, 32%, 85%, and 99% of cells). VLS-101 showed no efficacy in the lowest-expressing RS-PDX but induced complete remissions in those with higher levels of ROR1 expression. Responses were maintained during the posttherapy period, particularly after higher VLS-101 doses. In systemic ROR1+ RS-PDXs, VLS-101 dramatically decreased tumor burden in all RS-colonized tissues and significantly prolonged survival. Animals showed no adverse effects or weight loss. Our results confirm ROR1 as a target in RS and demonstrate the therapeutic potential of using an ADC directed toward ROR1 for the treatment of hematological cancers. A phase 1 clinical trial of VLS-101 (NCT03833180) is ongoing in patients with RS and other hematological malignancies.

17 July 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ANArianna Di Napoli
Arianna Di Napoli
GPGiuseppina Pepe
Giuseppina Pepe
EGEnrico Giarnieri
Enrico Giarnieri
CCClaudia Cippitelli
Claudia Cippitelli
ABAdriana Bonifacino
Adriana Bonifacino
MGMaria Rosaria Giovagnoli
Maria Rosaria Giovagnoli
Late breast implant seroma may be the presentation of a breast implant-associated anaplastic large cell lymphoma (BI-ALCL), which claims for a prompt recognition. However, BI-ALCL diagnosis on fine-needle aspiration (FNA) might be challenging for pathologists lacking experience with peri-implant breast effusions. Sixty-seven late breast implant seromas collected by FNA from 50 patients were evaluated by Papanicolaou smear stain and immunocytochemistry on cell blocks. A diagnostic algorithm based on the cellular composition, cell morphology and percentage of CD30+ cells was developed. Histological evaluation of the corresponding peri-prosthetic capsules was also performed. Most of the effusions (91% of the samples) were classified as reactive and 9% as BI-ALCL. In the BI-ALCL cases, medium-to-large atypical cells expressing CD30 represented more than 70% of the cellularity, whereas in in the reactive effusions CD30+ elements were extremely rare (<5%) and consisted of non-atypical elements. The reactive effusions were categorized into three patterns: i) acute infiltrate with prominent neutrophilic component (33% of the samples); ii) mixed infiltrate characterized by a variable number of neutrophils, lymphocytes and macrophages (30% of the samples); iii) chronic infiltrate composed predominantly of T lymphocytes or macrophages with only sporadic granulocytes (37% of the samples). The inflammatory cytological patterns were consistent with the histology of the corresponding capsules. Our results indicate that cytological analysis of late breast implant effusions, supported by the knowledge of the heterogeneous cytomorphological spectrum of late seromas, is a valuable approach for the early recognition of BI-ALCL.

1 February 2019 in Laboratory Investigation
Verified
Journal Article
Open access
PDF file
ANArianna Di Napoli
Arianna Di Napoli
LCLoris De Cecco
Loris De Cecco
Pier Paolo PiccalugaPier Paolo Piccaluga
Pier Paolo Piccaluga
MNMohsen Navari
Mohsen Navari
VCValeria Cancila
Valeria Cancila
GBGovind Bhagat
Govind Bhagat
Breast implant-associated anaplastic large cell lymphoma is a new provisional entity in the revised World Health Organization classification of lymphoid malignancies, the pathogenesis and cell of origin of which are still unknown. We performed gene expression profiling of microdissected breast implant-associated anaplastic large cell lymphoma samples and compared their transcriptional profiles with those previously obtained from normal T-cells and other peripheral T-cell lymphomas and validated expression of selected markers by immunohistochemistry. Our results indicate that most breast implant-associated anaplastic large cell lymphomas exhibit an activated CD4+ memory T-cell phenotype, which is associated with CD25 and FoxP3 expression. Gene ontology analyses revealed upregulation of genes involved in cell motility programs (e.g., CCR6, MET, HGF, CXCL14) in breast implant-associated anaplastic large cell lymphomas compared to normal CD4+ T-cells and upregulation of genes involved in myeloid cell differentiation (e.g., PPARg, JAK2, SPI-1, GAB2) and viral gene transcription (e.g., RPS10, RPL17, RPS29, RPL18A) compared to other types of peripheral T-cell lymphomas. Gene set enrichment analyses also revealed shared features between the molecular profiles of breast implant-associated anaplastic large cell lymphomas and other types of anaplastic large cell lymphomas, including downregulation of T-cell receptor signaling and STAT3 activation. Our findings provide novel insights into the biology of this rare disease and further evidence that breast implant-associated anaplastic large cell lymphoma represents a distinct peripheral T-cell lymphoma entity.

24 February 2014 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
GRGiuseppe Roscilli
Giuseppe Roscilli
MCManuela Cappelletti
Manuela Cappelletti
CVClaudia De Vitis
Claudia De Vitis
Gennaro CilibertoGennaro Ciliberto
Gennaro Ciliberto
ANArianna Di Napoli
Arianna Di Napoli
LALuigi Aurisicchio
Luigi Aurisicchio
Background: Tumor Associated Antigens are characterized by spontaneous immune response in cancer patients as a consequence of overexpression and epitope-presentation on MHC class I/II machinery. Matrix Metalloprotease 11 (MMP11) expression has been associated with poor prognosis for several cancer types, including breast and prostate cancer.Methods: MMP11 expression was determined by immunoistochemistry in breast and prostate cancer samples. Circulating MMP11 protein as well as the spontaneous immune responses against MMP11 were analyzed in a set of breast and prostate cancer patients.Results: In plasma samples MMP11 protein was present in 5/13 breast cancer patients and in 1/12 prostate cancer patients. An antibody response was observed in 7/13 breast cancer patients and in 3/12 prostate cancer patients.Conclusions: These findings further suggest MMP11 as a promising biomarker for these tumor types and a suitable target for cancer immunotherapy strategies.

2 December 2021 in EMBO Reports
Verified
Journal Article
Open access
PDF file
SSSara Sepe
Sara Sepe
FRFrancesca Rossiello
Francesca Rossiello
VCValeria Cancila
Valeria Cancila
FIFabio Iannelli
Fabio Iannelli
VMValentina Matti
Valentina Matti
FFFabrizio d’Adda di Fagagna
Fabrizio d’Adda di Fagagna
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.